The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: AFP and AFP-L3%, AlphaFetoprotein AFP and AFPL3
Also known as: CA 125 Tumor Marker, CA-125, Cancer Antigen 125, OC125, Ovarian Antigen
Also known as: CA 153, CA-Breast, Cancer Antigen 15-3, Cancer Antigen-Breast
Also known as: CA 199, Carbohydrate Antigen 19-9
Also known as: CA 2729, Cancer Ag 27-29
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Also known as: Carcinoembryonic Antigen
Also known as: Lactate Dehydrogenase LD, LDH
Also known as: Anti-TPO, Antithyroid Antibodies, TgAb, Thyroglobulin Antibodies TgAb, Thyroglobulin Antibody (TgAb), Thyroid Antibodies, Thyroid Autoantibodies, Thyroid Peroxidase Antibody (TPOAb), Thyroid Stimulating Immunoglobulin, Thyroperoxidase Antibody, Thyrotropin Receptor Antibodies, TPOAb, TSH Receptor Antibody, TSI
The CA-2. Cancer Screening - Women panel contains 10 tests with 43 biomarkers.
Brief Description: The CA-2 Cancer Screening - Women panel is a specialized diagnostic tool designed for the early detection and ongoing monitoring of various cancers specifically in women. It expands upon basic cancer screening by including additional markers that provide a wider range of detection and insight into different types of cancers. This panel is particularly valuable for women who are at increased risk due to genetic predispositions, family history, or environmental factors. It helps in the early identification of cancer, potentially improving the effectiveness of treatments and increasing the chances of successful outcomes.
Collection Method: Blood Draw
Specimen Type: Whole Blood and Serum
Test Preparation: No preparation required
The CA-2 Cancer Screening - Women panel may be ordered when a patient has symptoms that suggest the possibility of cancer, such as unexplained weight loss, persistent pain, abnormal masses, or changes in health that cannot be explained by other conditions. It is also recommended for women who have a high risk of cancer due to family history, genetic factors, or previous cancer occurrences. This panel assists in both the initial screening for cancerous conditions and the monitoring of changes in markers over time to manage and tailor treatment plans effectively.
The CA-2 panel includes a variety of tests, each targeting specific aspects related to cancer detection and monitoring:
Alpha-Fetoprotein and AFP-L3: These markers are significant for liver cancer detection. AFP-L3 is particularly useful for distinguishing between benign and malignant liver masses.
Amylase: Elevated levels can indicate pancreatic issues, which is crucial since pancreatic cancer can be particularly aggressive.
CA 125: This marker is primarily used for ovarian cancer screening and monitoring, providing critical insights into treatment response and disease progression.
CA 15-3: Used to monitor breast cancer, especially for tracking the effectiveness of treatment and detecting recurrence.
CA 19-9: While associated with pancreatic cancer, it can also be indicative of other gastrointestinal cancers.
CA 27.29: Another marker for breast cancer, useful in monitoring disease status and response to therapy.
Complete Blood Count with Differential and Platelets: Provides a general health overview and can detect abnormalities that may indicate cancer or side effects of treatment.
CEA: Commonly associated with colorectal cancer but can also indicate other types of cancer.
Lactate Dehydrogenase: High levels can suggest tissue damage from various cancers and is used to assess overall tumor burden.
Thyroglobulin Antibodies: Used in thyroid cancer patients to detect potential interference in thyroglobulin measurement, which can monitor cancer recurrence.
While the CA-2 panel provides a robust foundation for cancer screening, additional panels offer even greater depth and breadth in cancer diagnostics:
CA-3 Cancer Screening - Women panel: This panel adds critical tests such as Fecal Globin by Immunochemistry for colorectal cancer screening, Gastrin for potential issues related to excessive stomach acid production, and Total hCG Quantitative, which can detect pregnancy-associated cancers or serve as a tumor marker for certain cancers.
CA-4 Cancer Screening - Women panel: The most comprehensive panel, adding markers like Calcitonin, which is essential for detecting medullary thyroid cancer, and Des-Gamma-Carboxy-Prothrombin, a marker for hepatocellular carcinoma. This panel is the pinnacle of cancer screening capability, offering extensive coverage for those at high risk or undergoing cancer treatment.
This panel aids in detecting several types of cancers:
Liver Cancer: Marked by Alpha-Fetoprotein and its isoform AFP-L3, critical for early detection.
Pancreatic Cancer: Amylase levels can indicate pancreatic dysfunction, often an early sign of cancer.
Ovarian Cancer: CA 125 is a key biomarker for detecting and monitoring this cancer.
Breast Cancer: CA 15-3 and CA 27.29 are vital for monitoring treatment and potential recurrence.
Colorectal and Other Gastrointestinal Cancers: CEA and CA 19-9 are used to monitor these cancer types.
Healthcare professionals use these results to:
Guide Treatment Plans: Based on specific biomarker levels, treatment can be personalized.
Monitor Disease Progression: Regular testing provides insights into the effectiveness of the current treatment regimen.
Detect Early Signs of Cancer: Enabling timely and potentially more effective treatment.
The CA-2 Cancer Screening - Women panel is an essential tool in the fight against cancer. It allows for early detection and effective monitoring, crucial elements in improving treatment outcomes for women at risk or already diagnosed with cancer. This panel empowers patients and healthcare providers with the knowledge needed to make informed decisions about health and treatment strategies, emphasizing the importance of proactive health management.
We advise having your results reviewed by a licensed medical healthcare professional for proper interpretation of your results.